BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. Int J Mol Sci 2020;21:E4782. [PMID: 32640747 DOI: 10.3390/ijms21134782] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Rizkita LD, Astuti I. The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review. J Pharm Anal 2021;11:265-71. [PMID: 33782640 DOI: 10.1016/j.jpha.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Rathod R, Rathod A, Rahimabad PK, Duan J, Zhang H, Arshad SH, Karmaus W. Methylation of Host Genes Associated with Coronavirus Infection from Birth to 26 Years. Genes (Basel) 2021;12:1198. [PMID: 34440372 DOI: 10.3390/genes12081198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Di Salvo E, Di Gioacchino M, Tonacci A, Casciaro M, Gangemi S. Alarmins, COVID-19 and comorbidities. Ann Med 2021;53:777-85. [PMID: 34042528 DOI: 10.1080/07853890.2021.1921252] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tong X, Cheng A, Yuan X, Zhong X, Wang H, Zhou W, Xu X, Li Y. Characteristics of peripheral white blood cells in COVID-19 patients revealed by a retrospective cohort study. BMC Infect Dis 2021;21:1236. [PMID: 34886793 DOI: 10.1186/s12879-021-06899-7] [Reference Citation Analysis]
5 Jha NK, Sharma C, Hashiesh HM, Arunachalam S, Meeran MN, Javed H, Patil CR, Goyal SN, Ojha S. β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. Front Pharmacol 2021;12:590201. [PMID: 34054510 DOI: 10.3389/fphar.2021.590201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Luo W, Ding R, Guo X, Zhan T, Tang T, Fan R, Wang Y. Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3. Comput Biol Med 2022;145:105457. [PMID: 35366469 DOI: 10.1016/j.compbiomed.2022.105457] [Reference Citation Analysis]
7 Mirzaei R, Mahdavi F, Badrzadeh F, Hosseini-Fard SR, Heidary M, Jeda AS, Mohammadi T, Roshani M, Yousefimashouf R, Keyvani H, Darvishmotevalli M, Sani MZ, Karampoor S. The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Int Immunopharmacol 2021;90:107204. [PMID: 33221169 DOI: 10.1016/j.intimp.2020.107204] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
8 Allegra A, Tonacci A, Musolino C, Pioggia G, Gangemi S. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Front Immunol 2021;12:738915. [PMID: 34759921 DOI: 10.3389/fimmu.2021.738915] [Reference Citation Analysis]
9 Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, Doukas PG, Kavali L, Bukhari A, Gadiparthi C, Vageli DP, Kofteridis DP, Spandidos DA, Paoliello MMB, Aschner M, Docea AO. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol 2020;146:111769. [PMID: 32979398 DOI: 10.1016/j.fct.2020.111769] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 24.0] [Reference Citation Analysis]
10 Abd El Hadi SR, Zien El-Deen EE, Bahaa MM, Sadakah AA, Yassin HA. COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach. Drug Des Devel Ther 2021;15:3313-30. [PMID: 34366663 DOI: 10.2147/DDDT.S320320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kurup D, Malherbe DC, Wirblich C, Lambert R, Ronk AJ, Zabihi Diba L, Bukreyev A, Schnell MJ. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathog 2021;17:e1009383. [PMID: 33765062 DOI: 10.1371/journal.ppat.1009383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gozalbo-Rovira R, Gimenez E, Latorre V, Francés-Gómez C, Albert E, Buesa J, Marina A, Blasco ML, Signes-Costa J, Rodríguez-Díaz J, Geller R, Navarro D. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. J Clin Virol 2020;131:104611. [PMID: 32882666 DOI: 10.1016/j.jcv.2020.104611] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
13 Nagoor Meeran MF, Seenipandi A, Javed H, Sharma C, Hashiesh HM, Goyal SN, Jha NK, Ojha S. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19? Heliyon 2021;7:e05703. [PMID: 33490659 DOI: 10.1016/j.heliyon.2020.e05703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Philips CA, Rela M, Soin AS, Gupta S, Surendran S, Augustine P. Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients. J Clin Transl Hepatol 2021;9:947-59. [PMID: 34966658 DOI: 10.14218/JCTH.2021.00228] [Reference Citation Analysis]
15 Tsatsakis A, Calina D, Falzone L, Petrakis D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, Doukas PG, Kavali L, Bukhari A, Gadiparthi C, Vageli DP, Kofteridis DP, Spandidos DA, Paoliello MMB, Aschner M, Docea AO. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol 2020;146:111769. [PMID: 32979398 DOI: 10.1016/j.fct.2020.111769] [Reference Citation Analysis]
16 Siminea N, Popescu V, Sanchez Martin JA, Florea D, Gavril G, Gheorghe AM, Iţcuş C, Kanhaiya K, Pacioglu O, Popa IL, Trandafir R, Tusa MI, Sidoroff M, Păun M, Czeizler E, Păun A, Petre I. Network analytics for drug repurposing in COVID-19. Brief Bioinform 2021:bbab490. [PMID: 34864885 DOI: 10.1093/bib/bbab490] [Reference Citation Analysis]
17 Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, Hellman J, Jog S, Kesecioglu J, Kissoon N, Martin-Loeches I, Nunnally ME, Prescott HC, Rhodes A, Talmor D, Tissieres P, De Backer D. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med 2021;49:598-622. [PMID: 33591008 DOI: 10.1097/CCM.0000000000004895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Hamed ME, Naeem A, Alkadi H, Alamri AA, AlYami AS, AlJuryyan A, Alturaiki W, Enani M, Al-Shouli ST, Assiri AM, Alosaimi B. Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality. J Clin Immunol 2021. [PMID: 34232441 DOI: 10.1007/s10875-021-01061-z] [Reference Citation Analysis]
19 Stoy N. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front Immunol 2021;12:638446. [PMID: 33936053 DOI: 10.3389/fimmu.2021.638446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Litov L, Petkov P, Rangelov M, Ilieva N, Lilkova E, Todorova N, Krachmarova E, Malinova K, Gospodinov A, Hristova R, Ivanov I, Nacheva G. Molecular Mechanism of the Anti-Inflammatory Action of Heparin. Int J Mol Sci 2021;22:10730. [PMID: 34639073 DOI: 10.3390/ijms221910730] [Reference Citation Analysis]
21 Perrone T, Soldati G, Padovini L, Fiengo A, Lettieri G, Sabatini U, Gori G, Lepore F, Garolfi M, Palumbo I, Inchingolo R, Smargiassi A, Demi L, Mossolani EE, Tursi F, Klersy C, Di Sabatino A. A New Lung Ultrasound Protocol Able to Predict Worsening in Patients Affected by Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. J Ultrasound Med 2021;40:1627-35. [PMID: 33155689 DOI: 10.1002/jum.15548] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
22 Zhenyu H, Qiaoli Y, Guangxiang C, Maohua W. The effect of Ulinastatin on postoperative course in cardiopulmonary bypass patients in Asia: a meta-analysis of randomized controlled trials. J Cardiothorac Surg 2022;17:66. [PMID: 35379277 DOI: 10.1186/s13019-022-01811-z] [Reference Citation Analysis]
23 Altable M, de la Serna JM. Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets. Virus Res 2021;299:198347. [PMID: 33631219 DOI: 10.1016/j.virusres.2021.198347] [Reference Citation Analysis]
24 Nagoor Meeran MF, Javed H, Sharma C, Goyal SN, Kumar S, Jha NK, Ojha S. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon 2021;7:e05990. [PMID: 33585706 DOI: 10.1016/j.heliyon.2021.e05990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tan Q, He L, Meng X, Wang W, Pan H, Yin W, Zhu T, Huang X, Shan H. Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. J Nanobiotechnology 2021;19:173. [PMID: 34112203 DOI: 10.1186/s12951-021-00926-0] [Reference Citation Analysis]
26 Hussen J, Kandeel M, Hemida MG, Al-Mubarak AIA. Antibody-Based Immunotherapeutic Strategies for COVID-19. Pathogens. 2020;9. [PMID: 33167401 DOI: 10.3390/pathogens9110917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
27 Chone JS, Lima SVMA, Fronteira I, Mendes IAC, Shaaban AN, Martins MDRO, Sousa ÁFL. Factors associated with chemsex in Portugal during the COVID-19 pandemic. Rev Lat Am Enfermagem 2021;29:e3474. [PMID: 34468628 DOI: 10.1590/1518-8345.4975.3474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Dabbish AM, Yonis N, Salama M, Essa MM, Qoronfleh MW. Inflammatory pathways and potential therapies for COVID-19: A mini review. Eur J Inflamm 2021;19:205873922110029. [DOI: 10.1177/20587392211002986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Jha NK, Sharma C, Meeran MFN, Jha SK, Dwivedi VD, Gupta PK, Dey A, Kesari KK, Ojha S. Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19. Immuno 2021;1:285-304. [DOI: 10.3390/immuno1030020] [Reference Citation Analysis]
30 Zabolotnaya SV, Bogolepova AN, Tairova RT. [COVID-19-associated stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:5-10. [PMID: 34553575 DOI: 10.17116/jnevro20211210825] [Reference Citation Analysis]
31 Murdaca G, Di Gioacchino M, Greco M, Borro M, Paladin F, Petrarca C, Gangemi S. Basophils and Mast Cells in COVID-19 Pathogenesis. Cells 2021;10:2754. [PMID: 34685733 DOI: 10.3390/cells10102754] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kassem DH, Kamal MM. Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. Front Cell Dev Biol 2020;8:587866. [PMID: 33102489 DOI: 10.3389/fcell.2020.587866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wang SC, Wang YF. Cardiovascular protective properties of oxytocin against COVID-19. Life Sci 2021;270:119130. [PMID: 33513400 DOI: 10.1016/j.lfs.2021.119130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Papadopoulou G, Manoloudi E, Repousi N, Skoura L, Hurst T, Karamitros T. Molecular and Clinical Prognostic Biomarkers of COVID-19 Severity and Persistence. Pathogens 2022;11:311. [DOI: 10.3390/pathogens11030311] [Reference Citation Analysis]
35 Bagnato G, La Rosa D, Ioppolo C, De Gaetano A, Chiappalone M, Zirilli N, Viapiana V, Tringali MC, Tomeo S, Aragona CO, Napoli F, Lillo S, Irrera N, Roberts WN, Imbalzano E, Micari A, Ventura Spagnolo E, Squadrito G, Gangemi S, Versace AG. The COVID-19 Assessment for Survival at Admission (CASA) Index: A 12 Months Observational Study. Front Med (Lausanne) 2021;8:719976. [PMID: 34660631 DOI: 10.3389/fmed.2021.719976] [Reference Citation Analysis]
36 Soni S, Namdeo Pudake R, Jain U, Chauhan N. A systematic review on SARS-CoV-2-associated fungal coinfections. J Med Virol 2022;94:99-109. [PMID: 34570905 DOI: 10.1002/jmv.27358] [Reference Citation Analysis]
37 Yen CF, van den Berg P, Pepe DE. Infection prevention measures in acute care settings based on severe acute respiratory syndrome coronavirus 2 transmission patterns and risk: a review. Curr Opin Infect Dis 2021;34:346-56. [PMID: 34127582 DOI: 10.1097/QCO.0000000000000738] [Reference Citation Analysis]
38 Zapatero-Belinchón FJ, Moeller R, Lasswitz L, van Ham M, Becker M, Brogden G, Rosendal E, Bi W, Carriquí-Madroñal B, Islam K, Lenman A, Gunesch AP, Kirui J, Pietschmann T, Överby AK, Jänsch L, Gerold G. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience 2021;24:103469. [PMID: 34812415 DOI: 10.1016/j.isci.2021.103469] [Reference Citation Analysis]
39 Javed H, Meeran MFN, Jha NK, Ojha S. Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19. Front Plant Sci 2020;11:601335. [PMID: 33664752 DOI: 10.3389/fpls.2020.601335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]